Targeting pancreatic cancer energy metabolism, tumor growth, and metastasis
针对胰腺癌能量代谢、肿瘤生长和转移
基本信息
- 批准号:8883430
- 负责人:
- 金额:$ 52.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adenocarcinoma CellBiochemicalBioenergeticsBiological AssayCancer Cell GrowthCaringCell Culture TechniquesCell DeathCell ProliferationCellsCitric Acid CycleClinicCollaborationsCytolysisDiagnosisDiseaseDistantDrug TargetingEnergy MetabolismGenerationsGenus HippocampusGlucoseGlutamineGlycolysisGoalsGrowthHealthHumanImageImaging TechniquesIn VitroInvestigationMagnetic ResonanceMagnetic Resonance ImagingMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMass Spectrum AnalysisMeasuresMetabolicMetabolismMetforminMitochondriaModelingNeoplasm MetastasisNormal CellNutrientOxidative PhosphorylationPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPerceptionPharmaceutical PreparationsProductionPublic HealthPublishingPyruvateResearchRoleSCID MiceScientistSecond Primary NeoplasmsSeverity of illnessSignal PathwaySignal TransductionStagingSurvival RateTestingTimeTissuesTranslatingWarburg EffectWestern BlottingWorkXenograft procedureaerobic glycolysisanalogantitumor agentbasebioluminescence imagingcancer cellcancer therapycell growthcell motilitychemotherapyconventional therapycytotoxicitydesigndrug efficacydrug testingextracellulargemcitabinehuman FRAP1 proteinimprovedin vivoinhibitor/antagonistinnovationmetabolomicsmigrationneoplastic cellnovel therapeutic interventionpancreatic cancer cellspre-clinicalpreclinical efficacyresearch studytraffickingtumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Emerging research in cancer therapy is focused on exploiting the biochemical differences between cancer cell and normal cell metabolism. The Warburg effect is a fundamental change in many malignant cancer cells and is the shift in energy metabolism from oxidative phosphorylation to aerobic glycolysis. The common perception is that this metabolic reprogramming provides the cellular energy required for unregulated cell growth, invasion, and metastasis. Human pancreatic ductal adenocarcinoma (PDAC) is an incurable and highly aggressive human cancer. The median survival of the 75-80% of patients with malignant PDAC at the time of initial diagnosis is 6-months. Standard chemotherapy with the cytolytic drug gemcitabine provides a slight survival benefit. Thus, there is an unmistakable and critical unmet need for new therapies to treat patients with pancreatic cancer. The overall goal of this project is to develop new therapeutic approaches to inhibit PDAC malignancy. The significance of the proposed work lies in the use of relatively nontoxic mitochondria-targeted cationic drugs in combination with glycolytic and glutaminolytic energy metabolism inhibitors to decrease pancreatic cancer cell proliferation and metastasis. The overarching hypothesis is that a combination of glycolytic, glutaminolytic, and/or mitochondrial metabolism inhibitors with standard therapies will deplete ATP, decrease energy sensing, proliferation, and migration in vitro, and inhibit aerobic glycolysis and human PDAC tumor growth and metastasis in vivo. Studies in Aim 1 will use innovative high-throughput and mass spectroscopy-based metabolomics approach to investigate bioenergetic changes in glycolysis, tricarboxylic acid cycle, and glutaminolysis in human primary PDAC cells treated with mitochondria-targeted cationic agents, and/or inhibitors of energy metabolism. Aim 2 will use cell culture approaches to define the role for bioenergetic metabolism inhibitors in activating energy regulatory signaling pathways and altering PDAC growth, invasion, and migration. Aim 3 will use preclinical hyperpolarized magnetic resonance and bioluminescence imaging techniques to screen the in vivo efficacy of targeted drugs that inhibit energy metabolism, alone or in combination with traditional chemotherapy to mitigate PDAC growth and metastasis. The overall impact of the proposed work is two-fold: First, it will advance our understanding of the role of metabolism, energetics, and energy sensing in pancreatic cancer malignancy and second it will engender the design and testing of drugs that stifle energy production and which may ultimately be translated to the clinic.
描述(申请人提供):癌症治疗的新兴研究集中在利用癌细胞和正常细胞代谢之间的生化差异。Warburg效应是许多恶性癌细胞的根本变化,是能量代谢从氧化磷酸化到有氧糖酵解的转变。人们普遍认为,这种代谢重编程为不受调节的细胞生长、侵袭和转移提供了所需的细胞能量。人胰导管腺癌(PDAC)是一种无法治愈的高度侵袭性人类癌症。75-80%的恶性PDAC患者初始诊断时的中位生存期为6个月。使用溶细胞药物吉西他滨的标准化疗提供了轻微的生存益处。因此,有一个明确的和关键的需求,以新的治疗方法来治疗胰腺癌患者。该项目的总体目标是开发新的治疗方法来抑制PDAC恶性肿瘤。本研究的意义在于使用相对无毒的靶向线粒体的阳离子药物联合糖酵解和谷氨酰胺溶解能量代谢抑制剂来减少胰腺癌细胞的增殖和转移。总体假设是糖酵解、谷氨酰胺溶解和/或线粒体代谢抑制剂与标准疗法的结合将消耗ATP,降低体外能量感知、增殖和迁移,并抑制体内有氧糖酵解和人PDAC肿瘤的生长和转移。Aim 1的研究将使用创新的高通量和基于质谱的代谢组学方法来研究线粒体靶向的正离子剂和/或能量代谢抑制剂处理的人原代PDAC细胞中糖酵解、三羧酸循环和谷氨酰胺解的生物能量变化。目的2将使用细胞培养方法来定义生物能量代谢抑制剂在激活能量调节信号通路和改变PDAC生长、侵袭和迁移中的作用。Aim 3将使用临床前超极化磁共振和生物发光成像技术筛选抑制能量代谢的靶向药物,单独或联合传统化疗减轻PDAC生长和转移的体内疗效。这项工作的总体影响是双重的:首先,它将促进我们对代谢、能量学和能量感知在胰腺癌恶性肿瘤中的作用的理解;其次,它将促进抑制能量产生的药物的设计和测试,并可能最终转化为临床。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael B Dwinell其他文献
Michael B Dwinell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael B Dwinell', 18)}}的其他基金
Structure-based inhibition of chemokine signaling in the inflamed pancreas
基于结构的炎症胰腺趋化因子信号传导抑制
- 批准号:
10656002 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Biased chemokine receptor signaling in cancer progression
癌症进展中偏向的趋化因子受体信号传导
- 批准号:
10077789 - 财政年份:2019
- 资助金额:
$ 52.25万 - 项目类别:
Biased chemokine receptor signaling in cancer progression
癌症进展中偏向的趋化因子受体信号传导
- 批准号:
10541844 - 财政年份:2019
- 资助金额:
$ 52.25万 - 项目类别:
Biased chemokine receptor signaling in cancer progression
癌症进展中偏向的趋化因子受体信号传导
- 批准号:
10321201 - 财政年份:2019
- 资助金额:
$ 52.25万 - 项目类别:
Targeting pancreatic cancer energy metabolism, tumor growth, and metastasis
针对胰腺癌能量代谢、肿瘤生长和转移
- 批准号:
8696182 - 财政年份:2014
- 资助金额:
$ 52.25万 - 项目类别:
Targeting pancreatic cancer energy metabolism, tumor growth, and metastasis
针对胰腺癌能量代谢、肿瘤生长和转移
- 批准号:
9281690 - 财政年份:2014
- 资助金额:
$ 52.25万 - 项目类别:
相似海外基金
CAREER: Biochemical and Structural Mechanisms Controlling tRNA-Modifying Metalloenzymes
职业:控制 tRNA 修饰金属酶的生化和结构机制
- 批准号:
2339759 - 财政年份:2024
- 资助金额:
$ 52.25万 - 项目类别:
Continuing Grant
Systematic manipulation of tau protein aggregation: bridging biochemical and pathological properties
tau 蛋白聚集的系统操作:桥接生化和病理特性
- 批准号:
479334 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Operating Grants
Diurnal environmental adaptation via circadian transcriptional control based on a biochemical oscillator
基于生化振荡器的昼夜节律转录控制的昼夜环境适应
- 批准号:
23H02481 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Leveraging releasable aryl diazonium ions to probe biochemical systems
利用可释放的芳基重氮离子探测生化系统
- 批准号:
2320160 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Standard Grant
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:
10637251 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Structural and biochemical investigations into the mechanism and evolution of soluble guanylate cyclase regulation
可溶性鸟苷酸环化酶调节机制和进化的结构和生化研究
- 批准号:
10604822 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
- 批准号:
10716621 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Converting cytoskeletal forces into biochemical signals
将细胞骨架力转化为生化信号
- 批准号:
10655891 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Chemical strategies to investigate biochemical crosstalk in human chromatin
研究人类染色质生化串扰的化学策略
- 批准号:
10621634 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
EAGER: Elastic Electronics for Sensing Gut Luminal and Serosal Biochemical Release
EAGER:用于感测肠腔和浆膜生化释放的弹性电子器件
- 批准号:
2334134 - 财政年份:2023
- 资助金额:
$ 52.25万 - 项目类别:
Standard Grant